Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: ICH S1 Carcinogenicity Studies Guidelines | Statement: [ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, relatedTo, ICH S1 Carcinogenicity Studies Guidelines]

Target entity: ICH S1 Carcinogenicity Studies Guidelines
Context triple: [ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, relatedTo, ICH S1 Carcinogenicity Studies Guidelines]

• A. IARC Monographs on the Identification of Carcinogenic Hazards to Humans
  The IARC Monographs on the Identification of Carcinogenic Hazards to Humans are authoritative scientific evaluations that classify agents, mixtures, and exposures according to their potential to cause cancer in humans.
• B. Report on Carcinogens
  The Report on Carcinogens is an authoritative, periodically updated U.S. government publication that identifies and profiles substances known or reasonably anticipated to cause cancer in humans.
• C. ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
  ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
• D. ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
  ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
• E. ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
  ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals is an international guideline that outlines the nonclinical safety testing requirements for biotechnological products such as therapeutic proteins and monoclonal antibodies to support their clinical development and marketing authorization.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"

Entity: ICH S1 Carcinogenicity Studies Guidelines
Triple: [ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, relatedTo, ICH S1 Carcinogenicity Studies Guidelines]

The ICH S1 Carcinogenicity Studies Guidelines are international harmonized standards that outline when and how long-term animal carcinogenicity studies should be conducted to assess the cancer-causing potential of new pharmaceuticals.

Target entity: ICH S1 Carcinogenicity Studies Guidelines
Target entity description: The ICH S1 Carcinogenicity Studies Guidelines are international harmonized standards that outline when and how long-term animal carcinogenicity studies should be conducted to assess the cancer-causing potential of new pharmaceuticals.

• A. IARC Monographs on the Identification of Carcinogenic Hazards to Humans
  The IARC Monographs on the Identification of Carcinogenic Hazards to Humans are authoritative scientific evaluations that classify agents, mixtures, and exposures according to their potential to cause cancer in humans.
• B. Report on Carcinogens
  The Report on Carcinogens is an authoritative, periodically updated U.S. government publication that identifies and profiles substances known or reasonably anticipated to cause cancer in humans.
• C. ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
  ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
• D. ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
  ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
• E. ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
  ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals is an international guideline that outlines the nonclinical safety testing requirements for biotechnological products such as therapeutic proteins and monoclonal antibodies to support their clinical development and marketing authorization.
• F. None of above. chosen